Zhitong Finance App News, Sihuan Biotech (000518.SZ) announced that the company plans to acquire 65.6146% of the shares of Zhongrun Pharmaceutical Co., Ltd. (“Zhongrun Pharmaceutical”, the “target company”) in cash at a transaction price of 160 million yuan. After the transaction is completed, Zhongrun Pharmaceutical will become the company's holding subsidiary. At the same time, the target company will target the targeted capital reduction party to reduce its total holdings of 17.9817% of the target company's shares (corresponding to the target company's unpaid capital contribution of 337.1575 million yuan), and will not pay compensation for the capital reduction. After the capital reduction is completed, the company will hold 80% of the shares in the target company.

According to reports, Zhongrun Pharmaceutical is a pharmaceutical company engaged in drug research and development, production, and marketing. The main variety, oseltamivir phosphate, is the mainstream drug used in the field of anti-influenza. Market demand is continuous and seasonal. Relying on this core product, Zhongrun Pharmaceutical has formed a continuous and stable operating income and profit. The acquisition is conducive to achieving the company's business layout in the pharmaceutical field and building a dual business platform of “biological products+chemical preparations”.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.